AFT Pharmaceuticals - Continued execution of footprint expansion
AFT Pharmaceuticals continues to make inroads in expanding its strategic market footprint. Most recently, it announced the entry into China with...
157 Views
AFT Pharmaceuticals - FY24 Result — Roaring Revenue
We retain our OUTPERFORM rating with an unchanged target price of NZ$4.60 (roll forward and peers re-rate offsets earnings downgrades).
246 Views
AFT Pharmaceuticals - Growth underpinned by international momentum
AFT Pharmaceuticals’ FY24 results demonstrated record earnings and sales, with 24.8% year-on-year sales growth. Revenues of NZ$195.4m were driven...
234 Views
AFT Pharmaceuticals - Maxigesic IV’s Brazil entry, a foray into LATAM
AFT continues to expand its Maxigesic IV footprint with the announcement of a licensing agreement in Brazil, the largest pharma market in South...
161 Views
AFT Pharmaceuticals - Expanded R&D pipeline to fuel LT growth
While AFT continues to gain commercial traction from Maxigesic/ Combogesic IV sales in the US (launched by partner Hikma in Q1 CY24) and...
190 Views